This workshop is an excellent opportunity for urologists to interact directly with their peers to learn more about integrating in-office BPH therapies into their practices.
Minneapolis, MN (PRWEB) May 02, 2013
Urologix, Inc. (NASDAQ:ULGX) will host a Hands-On Workshop focused on demonstrating the proven efficacy and durability of minimally invasive, in-office BPH treatments at the 2013 AUA Annual Meeting in San Diego. The workshop provides an exclusive opportunity for the attendees to learn from experienced urologists about the latest procedure advancements and best practices for both Cooled ThermoTherapy™ and Prostiva® RF Therapy.
The workshop will be run by one of three proctors: Drs. J. Randolf Beahrs, Robert Pugach, or Craig Smith and takes place from Saturday afternoon through Tuesday morning inside the Urologix exhibit booth (#1405). Urologists can discuss procedure techniques, review the latest clinical data, and see how the products work up close.
“This workshop is an excellent opportunity for urologists to interact directly with their peers to learn more about integrating in-office BPH therapies into their practices.” said Greg Fluet, Chief Executive Officer of Urologix. “It is a great chance to learn how adopting both Cooled Thermotherapy and Prostiva RF Therapy enable comfortably treating a broader patient population in the safe and efficient setting of the urologist’s office.“
For more information or to attend the workshop, participants should stop by the Urologix Booth #1405 or contact Urologix directly at 888.229.0772 or firstname.lastname@example.org.
Urologix, Inc., based in Minneapolis, develops, manufactures, markets and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH). Urologix’s Cooled ThermoTherapy™ produces targeted microwave energy combined with a unique cooling mechanism to protect healthy tissue and enhance patient comfort. The Prostiva® RF Therapy System delivers radio frequency energy directly into the prostate destroying prostate tissue, reducing constriction of the urethra, and thereby relieving BPH symptoms. Both of these therapies provide safe, effective and lasting relief of obstruction and symptoms due to BPH. Prostiva is a registered trademark of Medtronic, Inc., used under license. All other trademarks are the property of Urologix.
Federal USA law restricts these devices to sale by or on the order of a physician. For more complete information about the benefits, risks and contraindications associated with Cooled ThermoTherapy and Prostiva RF Therapy, please refer to the product labeling which accompanies the device and can be found at http://www.urologix.com.
If you would like more information on this topic, please contact Karen Jackson at 513-484-2987 or kjackson(at)urologix(dot)com. To learn more about Urologix and its products and services, visit http://www.urologix.com.
The Urologix logo is available at http://www.urologix.com/clinicians/resource-library.php.
Urologix Media Contact
Urologix Investor Relations Contact